Innovent Biologics (HK:1801) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Innovent Biologics has announced that its TYVYT® (sintilimab injection) in combination with ELUNATE® (fruquintinib) has received conditional approval from China’s National Medical Products Administration for treating advanced endometrial cancer. This marks the eighth approval for TYVYT®, highlighting its expanding role in cancer treatment. With this approval, Innovent aims to offer new hope to patients with limited options, reinforcing its position in the immunotherapy market.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
